OSE Immunotherapeutics – equity proposition

OSE Immunotherapeutics – equity proposition

OSE Immunotherapeutics — 9 videos in collection

More on this equity

OSE Immunotherapeutics is a clinical-stage biotechnology company based in Nantes and Paris, France, and listed on Euronext Paris. The company is developing innovative immunotherapies across immuno-oncology and immuno-inflammation, with a renewed strategy focused on advancing its two lead proprietary clinical assets, Tedopi and lusvertikimab. This sharpened approach is designed to concentrate resources on programmes with the clearest potential to create value over the next several years.

We highlight four key points of OSE’s investment story.

  1. Tedopi is a late-stage cancer vaccine addressing a major unmet need in lung cancer.
  2. Tedopi offers broader potential beyond the lead programme.
  3. Lusvertikimab provides a differentiated opportunity in immuno-inflammation.
  4. A sharper strategy improves focus while preserving upside.

For further details, please refer to our latest research on OSE Immunotherapeutics.


You may also be interested in these:

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.